Deepti Pujare, MD
Endocrinology · Los Gatos
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 2
- 2 carriers
- Office
- 1
Offices
1 location · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Plans that list them
2 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Pujare’s office at (408) 934-7000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
2 of 2 plans
| Alignment Health Sutter Advantage +More (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A157059 · Current
Licensed to practise in California · since 2018 · expires 2028-07-31 · New York Medical College.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Original Medicare doctor bills
$208,046
Medicare paid this office $208,046 for 290 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Injection, denosumab, 1 mg | 27 | $44,575 | None |
| Return visit (30+ min) | 155 | $31,183 | $116 |
| New patient visit (60+ min) | 88 | $16,252 | $185 |
| New patient visit (45+ min) | 70 | $11,138 | $159 |
| Long return visit (40+ min) | 36 | $6,938 | $165 |
See all 9 services
| Injection, denosumab, 1 mg | 27 | $44,575 | None |
| Return visit (30+ min) | 155 | $31,183 | $116 |
| New patient visit (60+ min) | 88 | $16,252 | $185 |
| New patient visit (45+ min) | 70 | $11,138 | $159 |
| Long return visit (40+ min) | 36 | $6,938 | $165 |
| Fine needle aspiration biopsy using ultrasound guidance, first growth | 32 | $4,970 | $134 |
| Injection of drug or substance under skin or into muscle | 35 | $1,944 | $14 |
| Fine needle aspiration biopsy using ultrasound guidance, each additional growth | 15 | $1,344 | $56 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 17 | $1,292 | $29 |
Who their Medicare patients are
290 Original Medicare patients in 2024. Average age 75 · Women 75% · Also on Medicaid 11% · Health risk score 1.06. At or below the middle of the specialty; the typical endocrinology clinician is at 1.46.
Conditions among them: High blood pressure 70% · Diabetes 32% · Chronic kidney disease 22% · Coronary heart disease 18% · Atrial fibrillation 16% · Depression 16% · Cancer 13% · Heart failure 9% · COPD 9% · Dementia 6% · Stroke 5%.
The office billed $643,064, Medicare allowed $267,278 and paid $208,046; for 13,171 services of 14 kinds; $132,137 of it was for drugs given in the office and $75,908 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 290 | 13,171 | 75 | 1.06 | $643,064 | $208,046 |
| 2023 | 179 | 4,318 | 75 | 1.03 | $303,298 | $99,719 |
| 2022 | 52 | 265 | 74 | 1.25 | $51,734 | $16,377 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 6 services
| New patient visit (60+ min) | 117 | $22,504 | $192 |
| Injection, denosumab, 1 mg | 13 | $22,396 | None |
| Return visit (30+ min) | 76 | $15,558 | $114 |
| Long return visit (40+ min) | 40 | $7,431 | $165 |
| Fine needle aspiration biopsy using ultrasound guidance, first growth | 13 | $1,901 | $136 |
| Injection of drug or substance under skin or into muscle | 20 | $717 | $14 |
2022: 4 services
| New patient visit (60+ min) | 33 | $6,536 | $198 |
| Long return visit (40+ min) | 16 | $2,739 | $161 |
| Return visit (30+ min) | 15 | $1,976 | $116 |
| New patient visit (45+ min) | 11 | $1,588 | $144 |
Drugs they prescribed that Part D paid
$261,610
Pharmacies billed $261,610 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 738) in 2024. At or below the middle of the specialty; the typical endocrinology clinician is at 0%.
420 generic and 278 brand-name prescriptions · $261,610 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Jardiance | 48 | $75,854 | $1,580 |
| Mounjaro | 40 | $43,923 | $1,098 |
| Ozempic | 18 | $29,406 | $1,634 |
| Januvia | 18 | $25,031 | $1,391 |
| Basaglar Kwikpen U-100 | 18 | $5,897 | $328 |
See all 20 drugs
| Jardiance | 48 | $75,854 | $1,580 |
| Mounjaro | 40 | $43,923 | $1,098 |
| Ozempic | 18 | $29,406 | $1,634 |
| Januvia | 18 | $25,031 | $1,391 |
| Basaglar Kwikpen U-100 | 18 | $5,897 | $328 |
| Cinacalcet | 12 | $5,223 | $435 |
| Novolog Flexpen | 18 | $3,981 | $221 |
| Nano 2nd Gen Pen Needle | 30 | $3,146 | $105 |
| Humalog Kwikpen U-100 | 13 | $2,883 | $222 |
| Levothyroxine | 104 | $1,220 | $12 |
| Synthroid | 12 | $978 | $81 |
| Alendronate | 74 | $736 | $10 |
| Glipizide | 41 | $617 | $15 |
| Metformin Hcl Er | 23 | $351 | $15 |
| Methimazole | 28 | $332 | $12 |
| Pioglitazone | 11 | $259 | $24 |
| Glipizide Er | 17 | $248 | $15 |
| Glimepiride | 14 | $237 | $17 |
| Metformin | 29 | $194 | $7 |
| Dexamethasone | 13 | $20 | $2 |
Year by year
| 2024 | 738 | 156 | 0% (0) | 38% | $261,610 |
| 2023 | 338 | 89 | 0% (0) | 36% | $126,870 |
| 2022 | 110 | 27 | 0% (0) | 47% | $65,167 |
| 2021 | 96 | 26 | 0% (0) | None | $11,138 |
| 2020 | 68 | 28 | 0% (0) | None | $2,073 |
| 2019 | 133 | 57 | 0% (0) | None | $7,549 |
| 2018 | 126 | 48 | 0% (0) | None | $7,373 |
| 2017 | 27 | None | 0% (0) | None | $2,879 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 7 drugs
| Jardiance | 29 | $41,149 | $1,419 |
| Ozempic | 14 | $19,938 | $1,424 |
| Levothyroxine | 46 | $695 | $15 |
| Alendronate | 27 | $435 | $16 |
| Metformin | 21 | $425 | $20 |
| Glipizide | 30 | $281 | $9 |
| Methimazole | 18 | $233 | $13 |
2022: 2 drugs
| Forteo | 12 | $51,699 | $4,308 |
| Levothyroxine | 19 | $239 | $13 |
2021: 2 drugs
| Synthroid | 11 | $519 | $47 |
| Levothyroxine | 35 | $511 | $15 |
2019: 1 drug
| Furosemide | 11 | $120 | $11 |
Money from drug and device companies
$122 in 2025
| 2025 | 1 | 1 | None | $122 |
| 2024 | 2 | 2 | None | $286 |
| 2023 | 1 | 1 | None | $83 |
| 2022 | 1 | 1 | None | $48 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Ascendis Pharma Endocrinology | Yorvipath | $122 | 1 payment
|
See the published payment
| Ascendis Pharma Endocrinology | Meals · 2025-04-05 | Yorvipath | $122 |
See earlier years (2024, 2023, 2022)
2024: $286
| Beta Bionics | Ilet Bionic Pancreas | $164 | 1 payment
|
| Sanofi-Aventis U.S. | Tzield | $122 | 1 payment
|
2023: $83
| Beta Bionics | Ilet Bionic Pancreas | $83 | 1 payment
|
2022: $48
| Horizon Therapeutics plc | Tepezza | $48 | 1 payment
|
Professional record
- NPI
- 1639600125
- Licence
- CA A157059California A157059: Current · expires 2028-07-31
- Trained
- New York Medical College, 2017
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RE0101X (207RE0101X)
- Mailing address
- 325 Distel Cir, Los Altos, CA, 94022
- NPI first listed
- 2017-03-25
- NPI last updated
- 2022-08-29
- NPI record certified
- 2022-08-29
This is when the NPI record was last certified, not a medical board exam.